Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.

ABSTRACT:

Background

It has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer.

Methods

A total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific result

SUBMITTER: Gass P 

PROVIDER: S-EPMC6206705 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature